Authors and affiliation (s):
Ancy1, Kavyasree2, Philip Finny3, Shone Padinjarethil George3,*
1Department of Clinical Pharmacy, Nazareth College of Pharmacy, Othera, Thiruvalla, Kerala, INDIA.
2Department of Pharmacy Practice, Srinivas College of Pharmacy, Mangalore, Karnataka, INDIA.
3Department of Endocrinology, Believers Church Medical College Hospital, Thiruvalla, Kerala, INDIA.
ABSTRACT
Nivolumab, an immune checkpoint inhibitor, has revolutionized the treatment of various malignancies, including esophageal adenocarcinoma. However, its use is associated with immune-related Adverse Events (irAEs), including hypophysitis, a rare but potentially serious inflammation of the pituitary gland. This case report describes a patient with adenocarcinoma of the lower esophagus who developed hypophysitis after five cycles of nivolumab, presenting with hyponatremia and low cortisol levels. This case highlights the importance of recognizing and managing this endocrine irAE in patients undergoing immunotherapy.
Keywords: Nivolumab, Hypophysitis, Immune Checkpoint Inhibitor, Adverse Events, Esophageal Adenocarcinoma, Immunotherapy.